What are the benefits of estrogen therapy, and adjunct testosterone therapy when indicated, in postmenopausal women who have undergone hysterectomy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Benefits of Estrogen Therapy in Postmenopausal Women Without a Uterus

For postmenopausal women who have undergone hysterectomy, unopposed estrogen therapy provides effective relief of vasomotor symptoms (hot flashes, night sweats) and genitourinary symptoms, increases bone mineral density, reduces fracture risk, and may reduce colorectal cancer risk, though evidence is insufficient to definitively recommend it for chronic disease prevention alone.

Primary Benefits

Symptom Relief (FDA-Approved Indications)

Estrogen therapy is FDA-approved and most effective for 1:

  • Moderate to severe vasomotor symptoms (hot flashes, night sweats) - the most effective approved therapy
  • Moderate to severe vulvar and vaginal atrophy (dryness, itching, burning, dyspareunia)
  • Prevention of postmenopausal osteoporosis - though only when benefits outweigh risks and non-estrogen treatments have been considered

Bone Health

Unopposed estrogen demonstrates 2:

  • Increased bone mineral density (good evidence)
  • Reduced fracture risk (fair to good evidence)
  • In the WHI study, estrogen-only therapy probably reduces all clinical fractures (RR 0.73,95% CI 0.65 to 0.80) 3

Potential Cancer Benefits

  • Reduced colorectal cancer risk (fair evidence) 2
  • No increased breast cancer risk with estrogen-only therapy - in fact, the WHI showed probable slight reduction (RR 0.79,95% CI 0.61 to 1.01) 3, contrasting sharply with combined estrogen-progestin therapy which increases breast cancer risk

Quality of Life

Long-term follow-up data show 4:

  • Significant reduction in Kupperman index scores (from 26.7 to 12.0, P < 0.001) after 20 years
  • Improvements in overall quality of life
  • Beneficial effects on cardiovascular and bone health maintained over two decades

Important Risks to Consider

The USPSTF gives unopposed estrogen an "I" (insufficient evidence) recommendation for chronic disease prevention, noting both benefits and harms 2:

Cardiovascular Risks

  • Increased stroke risk (RR 1.33,95% CI 1.06 to 1.67) 3
  • Venous thromboembolism risk (RR 1.32,95% CI 1.00 to 1.74) 3
  • Probably makes little to no difference to coronary events (RR 0.94,95% CI 0.78 to 1.13) 3

Other Risks

  • Increased gallbladder disease requiring surgery (RR 1.78,95% CI 1.42 to 2.24) 3
  • Insufficient evidence on effects regarding dementia, cognitive function, or mortality 2

Testosterone Therapy as Adjunct

When to Consider Testosterone

Testosterone supplementation should be considered specifically for 5:

  • Hypoactive sexual desire disorder (HSDD) causing personal distress
  • Women with surgical menopause (bilateral oophorectomy) who experience more severe and rapid onset of sexual dysfunction
  • Persistent sexual symptoms despite adequate estrogen replacement

Evidence for Testosterone Benefits

In surgically menopausal women on estrogen therapy, transdermal testosterone (300 µg/d) demonstrates 5:

  • Increased satisfying sexual events: from 3 to 5 times per month (vs 4 with placebo) - a median increase of 1 additional satisfying event monthly
  • Reduced personal distress: 65-68% reduction (vs 40-48% with placebo)
  • Improved orgasm frequency: >115% increase (vs 38% with placebo)
  • Improvements in arousal, pleasure, self-image, and responsiveness

Additional research confirms 6:

  • At 300 µg/d transdermal testosterone, 2-3 fold increases in sexual fantasies, masturbation, and intercourse frequency
  • Improved psychological well-being scores (P=0.04 for composite scores)
  • Free testosterone levels reached high normal premenopausal range

A systematic review found 7:

  • Testosterone beneficially affects overall sexual functioning (SMD 0.38,95% CI 0.11-0.65)
  • Improves sexual desire on medium term (SMD 0.38,95% CI 0.19-0.56)

Critical Caveat on Testosterone

No FDA-approved testosterone formulation exists for women in the United States 8. Women often rely on compounded therapies with variable quality and oversight, or off-label use of male formulations at adjusted doses.

Clinical Decision Algorithm

Step 1: Assess Candidacy for Estrogen

Proceed with estrogen if:

  • Bothersome vasomotor or genitourinary symptoms present
  • Age <60 years OR <10 years since menopause onset
  • No absolute contraindications (see below)

FDA Contraindications 1:

  • Current/past breast cancer or estrogen-sensitive malignancy
  • Undiagnosed genital bleeding
  • Active/recent venous thromboembolism or arterial thromboembolism
  • Untreated hypertension
  • Active liver disease

Step 2: Optimize Estrogen Regimen

  • Use transdermal estradiol when cardiovascular or thrombotic risk is present (lower VTE and stroke risk than oral) 9, 10
  • Start with lowest effective dose - consider reducing dose at age 60 (e.g., from 0.05 to 0.025 mg/d transdermal) 4
  • For vaginal symptoms alone, use low-dose local vaginal estrogen preparations 1, 9

Step 3: Assess Need for Testosterone

Add testosterone if:

  • Persistent HSDD causing personal distress despite adequate estrogen
  • Especially if bilateral oophorectomy performed before natural menopause
  • Patient desires improvement in sexual function and psychological well-being

Dosing: Transdermal testosterone 300 µg/d has strongest evidence 5, 6

Step 4: Monitoring and Duration

  • Reassess annually: symptom control, side effects, risk factors
  • No arbitrary time limit - data support safe use up to 20 years in selected women 4
  • Individualize duration based on ongoing symptoms and risk-benefit profile
  • Monitor for acne and hirsutism with testosterone (most common reversible side effects)

Common Pitfalls to Avoid

  1. Do NOT add progestogen after hysterectomy unless residual endometrial tissue or endometriosis present 11 - progestogen increases breast cancer risk without benefit
  2. Do NOT use oral estrogen in women with elevated cardiovascular or thrombotic risk - transdermal has superior safety profile 9, 10
  3. Do NOT withhold estrogen solely based on age if symptoms persist and no contraindications exist - the 20-year safety data is reassuring 4
  4. Do NOT prescribe testosterone for general well-being or energy - indication is specifically HSDD 5
  5. Do NOT assume all estrogen formulations are equivalent - conjugated equine estrogens carry different risk profiles than 17β-estradiol 3, 10

References

1
Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2011

3
Research

Long-term hormone therapy for perimenopausal and postmenopausal women.

The Cochrane database of systematic reviews, 2025

5
Guideline

androgen therapy in women: a reappraisal: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2014

9
Guideline

treatment of symptoms of the menopause: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2015

Related Questions

What hormone replacement therapy medications should be prescribed for a postmenopausal woman, with options for an intact uterus versus after hysterectomy?
Should a woman who has had her cervix removed receive both estradiol and progesterone, and does the need depend on whether her uterus is intact?
Does progesterone alone help after a hysterectomy?
What are the benefits of hormone replacement therapy for female service members or leaders experiencing menopausal symptoms and for male service members or leaders with documented low testosterone?
Can a 61-year-old postmenopausal woman who has been postmenopausal for 7 years after a total hysterectomy (surgical removal of the uterus) and bilateral oophorectomy (surgical removal of both ovaries) take estrogen therapy?
What are the appropriate next steps after the death of a patient with known metastatic ovarian cancer who died three weeks ago?
Can the patient remain on duloxetine 60 mg daily and aripiprazole (Abilify) 10 mg daily?
What is the recommended systemic therapy for diffuse large B‑cell lymphoma (DLBCL) with cardiac involvement, and how should treatment be modified based on cardiac function?
For a patient with sinus node dysfunction and intact AV conduction, is a leadless atrial‑only (AAI) pacemaker available, and what are the appropriate pacing options?
What is the recommended pregabalin dosing regimen for an elderly patient with anxiety?
How many days should aspirin be discontinued before a partial mastectomy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.